Open Access
BIO Web Conf.
Volume 61, 2023
6th International Conference on Frontiers of Biological Sciences and Engineering (FBSE 2023)
Article Number 01020
Number of page(s) 4
Published online 21 June 2023
  • Torre, L.A., Siegel, R.L., Ward, E.M., et al. Global Cancer Incidence and Mortality Rates and Trends--An Update [J]. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, 2016, 25(1): 16-27. [Google Scholar]
  • Graham, T.A., Sottoriva, A.Measuring cancer evolution from the genome [J]. The Journal of pathology, 2017, 241(2): 183-191. [CrossRef] [PubMed] [Google Scholar]
  • Fu, J., Su, X., Li, Z., et al. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence [J]. Oncogene, 2021, 40(28): 4625-4651. [CrossRef] [PubMed] [Google Scholar]
  • Zhao, Y., Ye, W., Wang, Y.D., et al. HGF/c-Met: A Key Promoter in Liver Regeneration [J]. Frontiers in pharmacology, 2022, 13: 808855. [CrossRef] [PubMed] [Google Scholar]
  • Wang, Q., Yang, S., Wang, K., et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer [J]. Journal of hematology & oncology, 2019, 12(1): 63. [CrossRef] [PubMed] [Google Scholar]
  • Zhao, S., Wu, W., Jiang, H., et al. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? [J]. Frontiers in immunology, 2021, 12: 731527. [CrossRef] [PubMed] [Google Scholar]
  • Machado, V.A., Peixoto, D., Costa, R., et al. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors [J]. Bioorganic & medicinal chemistry, 2015, 23(19): 6497-6509. [CrossRef] [PubMed] [Google Scholar]
  • Wang, M.S., Zhuo, L.S., Yang, F.P., et al. Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold [J]. European journal of medicinal chemistry, 2020, 185: 111803. [CrossRef] [PubMed] [Google Scholar]
  • Gu, W., Dai, Y., Qiang, H., et al. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors [J]. Bioorganic chemistry, 2017, 72: 116-122. [CrossRef] [PubMed] [Google Scholar]
  • Zhuo, L.S., Xu, H.C., Wang, M.S., et al. 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development [J]. European journal of medicinal chemistry, 2019, 178: 705-714. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.